加载中
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
前收盘价
US$143.28
+US$2.49 · +1.77%
盘前
US$142.23
−US$1.05 · -0.73%
10月8日 6:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
日内区间
当前US$143.28
52周区间
当前US$143.28
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
86
深度低估
情绪
51
多空交织
风险
22
中等风险
动量
50
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
日内区间
当前US$143.28
52周区间
当前US$143.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 548.11亿 USD | 517.22亿 USD | 466.6亿 USD | 434.61亿 USD | 439.74亿 USD |
| 销货成本 | 136.9亿 USD | 128.27亿 USD | 124.72亿 USD | 115.82亿 USD | 117.35亿 USD |
| 毛利 | 411.22亿 USD | 388.95亿 USD | 341.88亿 USD | 318.79亿 USD | 322.39亿 USD |
| 研究与开发 | 107.42亿 USD | 100.22亿 USD | 113.71亿 USD | 91.72亿 USD | 86.41亿 USD |
| 销售、一般及管理费用 | 133.06亿 USD | 125.66亿 USD | 125.17亿 USD | 121.93亿 USD | 128.27亿 USD |
| 营业费用 | 240.48亿 USD | 243.51亿 USD | 244.19亿 USD | 239.33亿 USD | 221.83亿 USD |
| 利息收入 | 3.75亿 USD | 5.68亿 USD | 6.29亿 USD | 3.78亿 USD | 7100万 USD |
| 利息支出 | 11.87亿 USD | 10.36亿 USD | 8.76亿 USD | 8.35亿 USD | 9.05亿 USD |
| 折旧和摊销 | 53.52亿 USD | 60.69亿 USD | 82.77亿 USD | 67.05亿 USD | 55.97亿 USD |
| 营业利润 | 170.74亿 USD | 145.44亿 USD | 97.69亿 USD | 79.46亿 USD | 100.56亿 USD |
| 净利润 | 140.56亿 USD | 119.41亿 USD | 148.5亿 USD | 69.55亿 USD | 240.21亿 USD |
公司数据更新于 2026年10月8日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
Dimensional - International Value ETFDFIV1.27亿0.60%213.9亿 USD0.27%US$55.21-1.27%
Dimensional - International Core Equity Market ETFDFAI1.12亿0.63%177.81亿 USD0.18%US$41.15-1.15%
Dimensional - International Core Equity 2 ETFDFIC1.03亿0.69%150.1亿 USD0.22%US$37.34-1.11%
Avantis International Equity ETFAVDE8685.93万0.45%192.77亿 USD0.23%US$89.48-1.21%
Dimensional International High Profitability ETFDIHP8424.12万1.32%64.14亿 USD0.27%US$33.65-0.87%
Dimensional World ex U.S. Core Equity 2 ETFDFAX7423.14万0.60%123.72亿 USD0.28%US$37.08-1.23%
Fidelity Enhanced International ETFFENI4921.43万0.42%114.7亿 USD0.28%US$39.65-1.29%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH4198.67万4.10%10.3亿 USD0.13%US$28.1932+1.32%Dimensional - International Value ETFDFIVDimensional - International Core Equity Market ETFDFAIDimensional - International Core Equity 2 ETFDFICAvantis International Equity ETFAVDEDimensional International High Profitability ETFDIHPDimensional World ex U.S. Core Equity 2 ETFDFAXFidelity Enhanced International ETFFENIPortfolio Building Block World Pharma and Biotech Index ETFPBPHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
